Fairvalue-Calculator Fairvalue-Calculator
EN DE

Craneware plc (CRWRF) Fair Value & Analysis

Healthcare · US · Market cap $900M

Price$24.20
Fair Value$12.63
Upside-47.8%
Quality95/100
Evidence: High Range $9.48 – $15.79

Analysis

Craneware plc (CRWRF) currently trades at $24.20, while our model-based Fair Value estimate is $12.63 — implying the stock looks roughly 47.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. It provides solutions, such as Trisus Pricing Analyzer and Transparency, a solution that optimizes and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospective charge capture analytical application; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit solution for government and commercial payors. The company also offers Trisus Decision Support; Trisus Labor Productivity, which enables healthcare providers to manage, analyze, and plan the deployment of workforce; Trisus Medication Analytic solutions that prioritize, diagnose, and resolve issues in medication systems; and Trisus Supplies Assistant solutions which supplies charged…

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.